Menu Search
Equities

Axim Biotechnologies Inc

AXIM:QBB

Axim Biotechnologies Inc

Actions
  • Price (USD)0.0087
  • Today's Change0.001 / 9.85%
  • Shares traded32.72k
  • 1 Year change-64.49%
  • Beta1.1270
Data delayed at least 15 minutes, as of Jun 06 2024 15:14 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in USDView more

In 2023, Axim Biotechnologies Inc increased its cash reserves by 230.92%, or 109.18k. Cash Flow from Financing totalled 1.14m or 2,883.81% of revenues. In addition the company used 1.03m for operations while cash from investing was breakeven.
Cash flow per share-0.0171
Price/Cash flow per share--
Book value per share-0.0268
Tangible book value per share-0.0393
More ▼

Balance sheet in USDView more

Axim Biotechnologies Inc uses little or no debt in its capital structure.
Current ratio0.0201
Quick ratio--
Total debt/total equity--
Total debt/total capital--
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.